Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191631 | 1.00 | GSR (0.53) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL8836488 | 0.98 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Water SCHEMBL5501375 | 0.98 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL8836895 | 0.98 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL237121 | 0.94 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL1065054 | 0.94 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL8759024 | 0.94 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL8950857 | 0.94 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL3780217 | 0.94 | GSR (0.45) | GSRGNAI3GNAO1GNAI1CYP1A2 | |
| SCHEMBL5010336 | 0.93 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234222-A1 | Charge Reversal of Polyion Complexes | ROCHE MADISON INC. | 2008-09-25 | — | — | US | disclosed |
| US-7396919-B1 | Charge reversal of polyion complexes | MIRUS BIO CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1209971-A4 | CHARGE REVERSAL OF POLYION COMPLEXES | MIRUS CORP (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030236214-A1 | Charge reversal of polyion complexes and treatment of peripheral occlusive disease | WOLFF JON A (US) | 2003-12-25 | — | — | US | disclosed |
| EP-1098632-A4 | CHARGE REVERSAL OF POLYION COMPLEXES | MIRUS CORP (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1209971-A1 | CHARGE REVERSAL OF POLYION COMPLEXES | Mirus Corporation (US) | 2002-06-05 | — | — | EP | disclosed |
| US-20020052335-A1 | Charge reversal of polyion complexes | MIRUS BIO CORPORATION | 2002-05-02 | — | — | US | disclosed |
| EP-1098632-A1 | CHARGE REVERSAL OF POLYION COMPLEXES | Mirus Corporation (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2001013723-A1 | CHARGE REVERSAL OF POLYION COMPLEXES | MIRUS CORPORATION (US) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000003694-A1 | CHARGE REVERSAL OF POLYION COMPLEXES | MIRUS CORPORATION (US) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052335-A1 | Charge reversal of polyion complexes | POLRMT, PARN, POLN | GSR 1991/4885GNAI3 1780/4885GNAO1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.